The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities
Open accessAbstract
Identification of unintended drug effects, specifically drug repurposing opportunities and adverse drug events, maximizes the benefit of a drug and protects the health of patients. However, current observational research methods are subject to several biases. These include confounding by indication, reverse causality and missing data. We propose that Mendelian randomization (MR) offers a novel approach for the prediction of unintended drug effects. In particular, we advocate the synthesis of evidence from this method and other approaches, in the spirit of triangulation, to improve causal inferences concerning drug effects. MR addresses some of the limitations associated with the existing methods in this field. Furthermore, it can be applied either before or after approval of the drug, and could therefore prevent the potentially harmful exposure of patients in clinical trials and beyond. The potential of MR as a pharmacovigilance and drug repurposing tool is yet to be realized, and could both help prevent adverse drug events and identify novel indications for existing drugs in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816 · cited 1×
“Some methods are potentially more robust to certain types of pleiotropy, such as the weighted median and MR-Egger regression methods: these methods are discussed in detail elsewhere.(70,71) 2086 International Journal of Epidemiology, 2017, Vol.”
MethodBowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922 · cited 1×
“Some methods are potentially more robust to certain types of pleiotropy, such as the weighted median and MR-Egger regression methods: these methods are discussed in detail elsewhere.(70,71) 2086 International Journal of Epidemiology, 2017, Vol.”
MethodEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
The GTEx Consortium, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young, T. R., Gelfand, E. T., Trowbridge, C. A., Maller, J. B., Tukiainen, T., et al. (2015) · Science · doi:10.1126/science.1262110 · Cited by 5,062
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Self-citationSilverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483 · cited 1×
“mechanisms to be made.(20,60,61) This process is illustrated in Figure 2.”
BackgroundKathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386 · cited 1×
“(24,30) Swerdlow et al found “each additional rs17238484-G allele was associated with a mean 0·06 mmol/L (95% CI 0·05–0·07) lower LDL cholesterol and higher body weight (0·30 kg, 0·18–0·43), waist circumference (0·32 cm, 0·16–0·47), plasma insulin concentration (1·62%, 0·53–2·72), and plasma glucose concentration (0·2…”
Mendelian randomization: prospects, potentials, and limitations
Smith, G. D. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh132 · Cited by 1,222
Self-citationTriangulation in aetiological epidemiology
Lawlor, D. A., Tilling, K., & Davey Smith, G. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyw314 · Cited by 1,129
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604304 · Cited by 743
Swerdlow, D. I., Preiss, D., Kuchenbaecker, K. B., Holmes, M. V., Engmann, J. E. L., Shah, T., Sofat, R., Stender, S., Johnson, P. C. D., Scott, R. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61183-1 · Cited by 680
Self-citationMendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679 · cited 2×
“Therefore, careful consideration of the exposure and its timing must be made to avoid misinterpretation of results.(12,72) For example, some exposures are cumulative whereby repeated exposure, over a sustained period, results in the outcome.”
BackgroundMethodSelf-citationSmith, G. D., Lawlor, D. A., Harbord, R., Timpson, N., Day, I., & Ebrahim, S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040352 · Cited by 569
Self-citationNarrative review: statin-related myopathy
Joy, T. R., & Hegele, R. A. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00009 · Cited by 453
Ference, B. A., Majeed, F., Penumetcha, R., Flack, J. M., & Brook, R. D. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.020 · Cited by 407
Withdrawal of Cerivastatin from the World Market
Furberg, C. D., & Pitt, B. (2001) · Trials · doi:10.1186/cvm-2-5-205 · Cited by 400
Lotta, L. A., Sharp, S. J., Burgess, S., Perry, J. R. B., Stewart, I. D., Willems, S. M., Luan, J., Ardanaz, E., Arriola, L., Balkau, B., et al. (2016) · JAMA · doi:10.1001/jama.2016.14568 · Cited by 394
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
Schmidt, A. F., Swerdlow, D. I., Holmes, M. V., Patel, R. S., Fairhurst-Hunter, Z., Lyall, D. M., Hartwig, F. P., Horta, B. L., Hyppönen, E., Power, C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30396-5 · Cited by 380 · cited 1×
“Other genetic studies have found similar results.(26,27,62)”
Paternoster, L., Tilling, K., & Davey Smith, G. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006944 · Cited by 271
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
Robinson, J. G., Rosenson, R. S., Farnier, M., Chaudhari, U., Sasiela, W. J., Merlet, L., Miller, K., & Kastelein, J. J. P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.037 · Cited by 197
Davey Smith, G. (2011) · Genes & Nutrition · doi:10.1007/s12263-010-0181-y · Cited by 134 · cited 1×
“(43,44) Consequently, if a genetic variant is associated with an outcome through its association with a drug effect (and no other pathway), it is likely to be because the genetic variant causes the outcome.”
BackgroundIn silico assessment of adverse drug reactions and associated mechanisms
Ivanov, S. M., Lagunin, A. A., & Poroikov, V. V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.018 · Cited by 49
Cited by
Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians
Davies, N. M., Holmes, M. V., & Davey Smith, G. (2018) · BMJ · doi:10.1136/bmj.k601 · Cited by 4,404
Self-citationEvaluating the potential role of pleiotropy in Mendelian randomization studies
Hemani, G., Bowden, J., & Davey Smith, G. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy163 · Cited by 1,496
Zheng, J., Haberland, V., Baird, D., Walker, V., Haycock, P., Hurle, M., Gutteridge, A., Erola, P., Liu, Y., Luo, S., et al. (2019) · doi:10.1101/627398 · Cited by 812
Self-citationUsing genetic data to strengthen causal inference in observational research
Pingault, J.-B., O’Reilly, P. F., Schoeler, T., Ploubidis, G. B., Rijsdijk, F., & Dudbridge, F. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0020-3 · Cited by 444
Mendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.1 · Cited by 266
Self-citation
Metadata
- Authors
- Walker, V. M., Davey Smith, G., Davies, N. M., & Martin, R. M.
- Venue
- International Journal of Epidemiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10-11
- Volume
- 46
- Issue
- 6
- Pages
- 2078-2089
- ISSN
- 0300-5771 (ISSN-L)
- 1464-3685
- OpenAlex
- W2951435941
- Cited by
- 217
- References
- 27
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.